Distribution of therapeutic monoclonal antibodies into ascites in advanced gastric cancer patients with peritoneal metastasis: case reports and literature review

Smyth EC, Nilsson M, Grabsch HI, van Grieken NCT, Lordick F (2020) Gastric cancer. Lancet 396:635–648. https://doi.org/10.1016/S0140-6736(20)31288-5

CAS  Article  PubMed  Google Scholar 

Spratlin JL, Cohen RB, Eadens M, Gore L, Camidge DR, Diab S, Leong S, O’Bryant C, Chow LQ, Serkova NJ, Meropol NJ (2010) Phase I pharmacologic and biologic study of Ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 28:780–787. https://doi.org/10.1200/JCO.2009.23.7537

CAS  Article  PubMed  PubMed Central  Google Scholar 

Wang C, Thudium KB, Han M, Wang XT, Huang H, Feingersh D, Garcia C, Wu Y, Kuhne M, Srinivasan M (2014) In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res 2:846–856. https://doi.org/10.1158/2326-6066.CIR-14-0040

CAS  Article  PubMed  Google Scholar 

Liu L (2018) Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins. Protein Cell 9:15–32. https://doi.org/10.1007/s13238-017-0408-4

CAS  Article  PubMed  Google Scholar 

Tahara M, Ohtsu A, Boku N, Nagashima F, Muto M, Sano Y, Yoshida M, Mera K, Hironaka S, Tajiri H, Yoshida S (2001) Sequential methotrexate and 5-fluorouracil therapy for gastric cancer patients with peritoneal dissemination: a retrospective study. Gastric Cancer 4:212–218. https://doi.org/10.1007/s10120-001-8012-x

CAS  Article  PubMed  Google Scholar 

Kobayashi M, Sakamoto J, Namikawa T, Okamoto K, Okabayashi T, Ichikawa K, Araki K (2006) Pharmacokinetic study of paclitaxel in malignant ascites from advanced gastric cancer patients. World J Gastroenterol 12:1412–1415. https://doi.org/10.3748/wjg.v12.i9.1412

CAS  Article  PubMed  PubMed Central  Google Scholar 

Tamegai H, Kaiga T, Kochi M, Fujii M, Kanamori N, Mihara Y, Funada T, Shimizu H, Jinno D, Takayama T (2013) Pharmacokinetics of docetaxel in gastric cancer patients with malignant ascites. Cancer Chemother Pharmacol 71:727–731. https://doi.org/10.1007/s00280-012-2066-9

CAS  Article  PubMed  Google Scholar 

Mehrotra R, De Gaudio R, Palazzo M (2004) Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness. Intensive Care Med 30:2145–2156. https://doi.org/10.1007/s00134-004-2428-9

Article  PubMed  Google Scholar 

Delauter BJ, Ramanathan RK, Egorin MJ, Stover LL, Zuhowski EG, Plunkett W, Zamboni WC (2000) Pharmacokinetics of gemcitabine and 2′,2′-difluorodeoxyuridine in a patient with ascites. Pharmacotherapy 20:1204–1207. https://doi.org/10.1592/phco.20.15.1204.34586

CAS  Article  PubMed  Google Scholar 

Kaneko T, Doki K, Yamada T, Niisato Y, Homma M (2021) Bevacizumab distribution into ascitic fluid decreases serum drug exposure: a case of metastatic colon cancer. Ther Drug Monit 43:813–814. https://doi.org/10.1097/FTD.0000000000000926

Article  PubMed  Google Scholar 

Hiroshima Y, Tajima K, Shiono Y, Suzuki I, Kouno K, Yamamoto M, Kato Y, Kato T (2012) Rituximab pharmacokinetics in ascites and serum in the treatment of follicular lymphoma with massive ascites. Ann Hematol 91:1499–1500. https://doi.org/10.1007/s00277-012-1410-9

Article  PubMed  PubMed Central  Google Scholar 

Shima T, Kamezaki K, Higashioka K, Takashima S, Yoshimoto G, Kato K, Muta T, Takenaka K, Iwasaki H, Miyamoto T, Akashi K (2016) Ascites retention during Mogamulizumab treatment in a patient with adult T-cell leukemia/lymphoma. Intern Med 55:1793–1796. https://doi.org/10.2169/internalmedicine.55.5987

Article  PubMed  Google Scholar 

Kovarik J, Breidenbach T, Gerbeau C, Korn A, Schmidt A-G, Nashan B (1998) Disposition and immunodynamics of basiliximab in liver allograft recipients. Clin Pharmacol Ther 64:66–72. https://doi.org/10.1016/S0009-9236(98)90024-8

CAS  Article  PubMed  Google Scholar 

European medicines agency (EMA) (2022) Cyramza-epar product information. Available at http://www.ema.europa.eu. Accessed 16 Jan 2022.

European medicines agency (EMA) (2022) Opdivo-epar scientific discussion. Available at http://www.ema.europa.eu. Accessed 16 Jan 2022.

Cavazzoni E, Bugiantella W, Graziosi L, Franceschini MS, Donini A (2012) Malignant ascites: pathophysiology and treatment. Int J Clin Oncol 18:1–9. https://doi.org/10.1007/s10147-012-0396-6

Article  PubMed  Google Scholar 

Suzuki H, Yamada T, Sugaya A, Ueyama S, Yamamoto Y, Moriwaki T, Hyodo I (2021) Retrospective analysis for the efficacy and safety of nivolumab in advanced gastric cancer patients according to ascites burden. Int J Clin Oncol 26:370–377. https://doi.org/10.1007/s10147-020-01810-x

CAS  Article  PubMed  Google Scholar 

Yildirim B, Sezgin N, Sari R, Sevinc A, Hilmioglu F (2002) Complement and immunoglobulin levels in serum and ascitic fluid of patients with spontaneous bacterial peritonitis, malignant ascites, and tuberculous peritonitis. South Med J 95:1158–1162

Article  Google Scholar 

Alexandrakis MG, Moschandrea JA, Koulocheri SA, Kouroumalis E, Eliopoulos GD (2000) Discrimination between malignant and nonmalignant ascites using serum and ascitic fluid proteins in a multivariate analysis model. Dig Dis Sci 45:500–508. https://doi.org/10.1023/a:1005437005811

CAS  Article  PubMed  Google Scholar 

Nakamura H, Hanafusa N, Kitamura K, Nakamura H, Sekihara H, Shimizu K, Anayama M, Makino Y, Tamura K, Nagasawa M (2020) Biochemical evaluation of processed ascites in patients undergoing cell-free and concentrated ascites reinfusion therapy. Ther Apher Dial 24:516–523. https://doi.org/10.1111/1744-9987.13541

CAS  Article  PubMed  Google Scholar 

留言 (0)

沒有登入
gif